# Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

Source: https://onco.cc/trials/nct07007728/  
OnCo record `nct07007728` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of bevacizumab (glioblastoma use) and cAPOX (capecitabine, oxaliplatin) in colorectal cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.

## Summary

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis is a phase 2, interventional study registered as NCT07007728 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 54 participants, started 2025-06-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: Iparomlimab/Tuvonralimab; Bevacizumab + CAPEOX; Surgical resection ± ablation or stereotactic radiotherapy (if applicable). Conditions listed: Colorectal Neoplasms; Secondary Malignant Neoplasm of Liver. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: "Pathologically confirmed colorectal adenocarcinoma with liver metastases confirmed by pathology or imaging;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07007728
- Phase: 2
- Setting: Efficacy and Safety of Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy in Patients With Right-Sided or RAS-mutant, Microsatellite Stable, Initially Unresectable Colorectal Cancer Liver Metastasis: A Prospective, Open-Label, Single-Arm, Single-Center, Phase II Clinical Trial
- Sponsor: Peking University Cancer Hospital & Institute
- Enrolled: 54

## Sources

- ClinicalTrials.gov NCT07007728: https://clinicaltrials.gov/study/NCT07007728

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Thermal ablation (RFA, microwave, cryo)](https://onco.cc/technologies/thermal-ablation/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07007728.json